Coronary/Structural Heart

Eicosapentaenoic Acid (EPA) Levels From VASCEPA® (Icosapent Ethyl) in REDUCE-IT® Strongly Correlated with Cardiovascular Outcomes

Serum EPA Levels Showed Approximately 400% Increase Following Administration of VASCEPA  High EPA Levels Associated with Substantial Reductions in Multiple Cardiovascular Endpoints Including Heart Failure and Total Mortality Amarin to Webcast Discussion of Presented Data March 30, 5:30 – 6:30 p.m., Eastern Time DUBLIN, Ireland and BRIDGEWATER, N.J., March 30, […]

Cytokinetics Announces Baseline Characteristics from GALACTIC-HF at ACC.20/WCC Virtual

Top-line Results for GALACTIC-HF Expected in Q4 2020 SOUTH SAN FRANCISCO, Calif., March 30, 2020 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that patient baseline characteristics and demographics from GALACTIC-HF (Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure), the Phase 3 event driven cardiovascular outcomes clinical trial of omecamtiv mecarbil, were published during the […]

BRILINTA reduced bleeding vs dual therapy in high-risk coronary patients in sub-analyses from Phase IV TWILIGHT trial

BRILINTA monotherapy reduced bleeding complications with no increased risk of ischemic events in patients with diabetes undergoing percutaneous coronary intervention Consistent results were also observed in patients undergoing complex percutaneous coronary intervention WILMINGTON, Del.–(BUSINESS WIRE)–Results from two subgroup analyses of the Phase IV independent TWILIGHT trial funded by AstraZeneca showed BRILINTA (ticagrelor) […]

FARXIGA reduced the incidence of heart failure worsening or cardiovascular death in a sub-analysis from landmark Phase III DAPA-HF trial

New data showed consistent effect of FARXIGA in patients with heart failure with reduced ejection fraction, regardless of background therapy WILMINGTON, Del.–(BUSINESS WIRE)–New data from a sub-analysis of the landmark Phase III DAPA-HF (Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure) trial showed that AstraZeneca’s FARXIGA (dapagliflozin) reduced the incidence of […]

Benefits of bempedoic acid in hypercholesterolaemia further demonstrated by data presented at the American College of Cardiology’s 69th Annual Scientific Sessions Together with World Congress of Cardiology (ACC.20/WCC)

Bempedoic acid is being developed as a first-in-class, affordable, oral treatment which lowers low-density lipoprotein cholesterol (LDL-C), and which can be combined with other oral treatments to help lower cholesterol even further1,2,3,4,5 Data from Phase 2 study show a 40% reduction in LDL-C for patients with type 2 diabetes who […]

Investigational Drug Vericiguat Significantly Reduced the Risk of the Composite Endpoint of Heart Failure Hospitalization or Cardiovascular Death, Compared to Placebo, When Given in Combination with Available Heart Failure Therapies

Phase 3 VICTORIA Trial is the First Contemporary Outcomes Study Focused Exclusively on a Chronic Heart Failure Patient Population Following a Worsening Event KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of results from the VICTORIA trial, a Phase 3 […]

American Society For Preventive Cardiology (ASPC) Launches The American Journal Of Preventive Cardiology

JACKSONVILLE, Fla., March 25, 2020 /PRNewswire/ — The American Society for Preventive Cardiology (ASPC) launches the American Journal of Preventive Cardiology, one of the only journals dedicated solely to preventive cardiology in the U.S. “Preventive cardiology has witnessed exponential growth over the past few decades in the available clinical tools and new knowledge. We […]

CardioQuip MCH-1000™ Earns CE Mark Approval

Advanced temperature control technology to help European hospitals fighting COVID-19 outbreak COLLEGE STATION, Texas, March 26, 2020 /PRNewswire/ — CardioQuipTM, LLC, a medical device manufacturer focused on development and commercialization of patient temperature control and cardiovascular perfusion technology announced today it has received CE Mark approval for the MCH-1000TM Modular Cooler-Heater SeriesTM. The MCH-1000 Series of […]

MyoKardia Provides Clinical Trial Update in the Context of the COVID-19 Pandemic

Reaffirms Second Quarter 2020 Expected Timing for Topline Data from Phase 3 EXPLORER-HCM Clinical Trial of Mavacamten and Phase 2a Danicamtiv Study BRISBANE, Calif., March 26, 2020 (GLOBE NEWSWIRE) — MyoKardia, Inc. (Nasdaq: MYOK) today provided an update to the status of its clinical programs in the context of the COVID-19 […]

LivaNova Autonomic Regulation Therapy for Heart Failure Findings to be Presented at American College of Cardiology and World Congress of Cardiology Virtual Meeting

LONDON–(BUSINESS WIRE)–LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced two abstracts focused on implantable neuromodulation technology for patients with heart failure will be shared at this year’s American College of Cardiology and World Congress of Cardiology Virtual meeting (ACC.20/WCC). In lieu of traditional in-person presentations, ACC.20/WCC will […]